Dr. Prow is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
16668 530th Ave
Gilbert, IA 50105Phone+1 817-308-0919
Education & Training
- University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1995 - 1997
- Baylor College of MedicineResidency, Internal Medicine, 1992 - 1995
- Indiana University School of MedicineClass of 1992
Certifications & Licensure
- IA State Medical License 2007 - 2025
- TX State Medical License 1994 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Start of enrollment: 2003 Jan 01
- Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer Start of enrollment: 2014 Apr 01
Publications & Presentations
PubMed
- 56 citationsRandomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor–Associated Arthralgias in Early-Stage Breast Cancer: SW...N. Lynn Henry, Joseph M. Unger, Anne F. Schott, Louis Fehrenbacher, Patrick J. Flynn
Journal of Clinical Oncology. 2017-11-14 - 41 citationsGene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).Harry H. Yoon, Nathan R. Foster, Jeffrey P. Meyers, Preston D. Steen, DW Visscher
Annals of Oncology. 2016-02-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: